Antagonists of β-adrenergic receptors (β-ARs) have become a main therapeutic regimen for the treatment of heart failure even though the mechanisms of their beneficial effects are still poorly understood. Here, we used fluorescent resonance energy transfer-based (FRET-based) approaches to directly monitor activation of the β 1 -AR and downstream signaling. While the commonly used β-AR antagonists metoprolol, bisoprolol, and carvedilol displayed varying degrees of inverse agonism on the Gly389 variant of the receptor (i.e., actively switching off the β 1 -AR), surprisingly, only carvedilol showed very specific and marked inverse agonist effects on the more frequent Arg389 variant. These specific effects of carvedilol on the Arg389 variant of the β 1 -AR were also seen for control of beating frequency in rat cardiac myocytes expressing the 2 receptor variants. This FRET sensor permitted direct observation of activation of the β 1 -AR in living cells in real time. It revealed that β 1 -AR variants dramatically differ in their responses to diverse beta blockers, with possible consequences for their clinical use.
Introduction
Activation of cardiac β-adrenergic receptors (β-AR) by endogenous catecholamines plays a key role in the regulation of cardiac function. The heart contains at least 2 β-AR subtypes, termed β 1 -AR and β 2 -AR, and may also contain β 3 -ARs (1) . Stimulation of the β 1 -AR represents the strongest endogenous mechanism for increasing contractility and beating frequency of the mammalian heart (1). In human heart failure, which has become one of the leading causes of death and hospitalization (2) , the sympathetic nervous system is chronically activated to overcome the loss of cardiac output (3) . While this initially leads to compensation through a short-term increase in cardiac function, chronic stimulation of the cardiac β-AR system contributes to progression of the disease (4, 5) . These detrimental effects of chronic β-adrenergic signaling are attributed to the β 1 -AR subtype. Transgenic mice with cardiomyocyte-specific expression of the β 1 -AR develop progressive cardiac hypertrophy and heart failure in a manner similar to that seen in patients with heart failure (6) . Consequently, the development of receptor antagonists (7) has resulted in the single most effective therapeutic regimen to treat heart failure (8) .
Several common polymorphisms of the human β 1 -AR have been identified. Most importantly, the Arg-Gly polymorphism at amino acid position 389 (9, 10) has been associated with cardiac disease (11) . Position 389 is located near the seventh transmembrane domain of the receptor in the cytoplasmic tail, within a putative Gs protein-binding domain, corresponding to helix 8 in rhodopsin (12) (13) (14) . In vitro experiments indicated greater stimulation of adenylyl cyclase activity through the Arg389 variant of the β 1 -AR (10) . Recent studies showed that the Arg389 polymorphism is associated with a poor prognosis in heart failure (15) and predisposes to hypertension (16) . Moreover, patients carrying both the Arg389 variant of the β 1 -AR and a deletion variant of the presynaptic α 2c -AR receptor had a greatly enhanced risk of developing heart failure (11) .
While all these data confirm the concept that chronic β 1 -AR signaling is detrimental, it is currently unclear how patients with an inherently hyperfunctional β-AR system should be treated and what substances are effective.
Contradictory results have been reported regarding whether the 389 polymorphism determines the sensitivity of the response to beta blocker treatment (for reviews, see refs. [17] [18] [19] . While some studies found that the presence of the Arg389 allele of the β 1 -AR is associated with a greater heart rate or blood pressure response to beta blockers (15, (20) (21) (22) (23) (24) , others found no association (25) (26) (27) . These discrepancies may be attributed to the relatively small sizes of the cohorts and the complex and highly regulated physiological parameters that were studied.
To overcome these limitations, we developed a fluorescent resonance energy transfer (FRET) approach to record directly and in real time the conformational changes of the receptor protein that lead to its activation. Based on the resonance energy transfer between fluorophores of overlapping emission spectra, FRET has evolved to become a potent method of studying protein-protein interactions and also, increasingly, dynamic conformational changes within proteins (28, 29) . To study G protein-coupled receptor signaling, sensors for receptor and G protein activation (30) (31) (32) (33) as well as for the detection of various second messengers have been developed (34, 35) . To determine the degree of activation of the β 1 -AR in living cells in real time, we measured FRET between a mutant cyan fluorescent protein, Cerulean (Cer), fused to the carboxy terminus of the human β 1 -AR and a yellow fluorescent protein (YFP) inserted into the third intracellular loop. A comparison of the activation characteristics of the 2 frequently occurring receptor polymor-phisms Arg389 and Gly389 revealed substantial differences in the response of these receptor variants to beta blockers.
Results

Functional characterization of the β 1 -AR-FRET sensor.
We generated a mutant β 1 -AR into which the cyan- and yellow-emitting variants of GFP (Cer and YFP) were inserted at the C terminus and in the third intracellular loop of the receptor, respectively. This FRET receptor construct is referred to as the β 1 -AR sensor ( Figure 1A ). Confocal microscopy showed that the β 1 -AR sensor was well expressed and targeted to the cell membrane ( Figure 1B) . Signals recorded from single HEK293 cells expressing the β 1 -AR sensor were then analyzed at emission wavelengths of 480 nm (Cer) and 535 nm (YFP) upon excitation at 436 nm (Cer excitation). Excitation at 436 nm resulted in significant emission at 535 nm, characteristic for FRET. Bleaching of the acceptor YFP with intense light at 480 nm, resulting in an 80% reduction of the 535 nm emission, caused an increase of the emission at 480 nm of 20%, indicating that the emission at 535 nm was indeed due to FRET ( Figure 1C ). The ratio F 535 /F 480 , where F 535 and F 480 are the emission intensities at 535 nm and 480 nm, respectively (corrected for spillover and direct excitation of YFP; refs. 30, 33) , was used in subsequent experiments as a measure of FRET. We then investigated the effect of the endogenous agonist norepinephrine (NE) on the FRET signal of the β 1 -AR sensor. Superfusion of transiently transfected HEK293 cells with 10 μM NE led to a simultaneous increase in Cer emission and decrease in YFP emission. This amounted to an average decrease of the F 535 /F 480 FRET ratio by approximately 4% ( Figure 1D ). This loss of FRET reflects the agonist-induced receptor activation, as has been described for other receptor constructs (33, 36, 37) (Figure 1D ).
We then investigated in detail how closely the β 1 -AR-FRET sensor reflected the pharmacological and signaling characteristics of the wild-type receptor. Concentration-response curves of β 1 -AR sensor activation for NE and isoproterenol (Iso) yielded half-maximal effective concentration (EC 50 ) of 1.8 ± 0.2 μM and 230 ± 40 nM, respectively (Figure 2A) , which is similar to the wild-type receptor characteristics (K i [NE] 3.6 μM; K i [Iso] 220 nM) (38) . The fast agonist-induced decrease of the FRET signal corresponding to activation of the receptor was rapidly and completely reversed upon application of the receptor antagonist propranolol. Propranolol had no effect on the basal FRET signal when it was applied alone ( Figure 2B ). Finally, we tested the capacity of the β 1 -AR sensor to induce production of cAMP. HEK293 cells were cotransfected with the FRET-based cAMP sensor Epac1-camps and the β 1 -AR sensor or with the unlabeled β 1 -AR. To block endogenously expressed β 2 -ARs, β 1 -AR activation with Iso (1 nM) was carried out in the presence of the specific β 2 -AR antagonist ICI 118551 (200 nM). We then determined FRET of Epac1-camps, which corresponds to cAMP production (34) . As shown in Figure 2C , induction of cAMP production through the β 1 -AR sensor closely resembled the signal of the unlabeled receptor with respect to both the kinetics and the extent of cAMP formation. This FRET signal must be entirely due to the cAMP sensor, as 1 nM Iso does not lead to detectable activation of the β 1 -AR sensor (see Figure 2A ) and also because the cAMP sensor is expressed at higher levels throughout the cytosol and yields a much higher FRET response compared with the β 1 -AR sensor. To assess the expression levels of the 2 sensors, we used the YFP signal of Epac1-camps-expressing cells as compared with β 1 -AR sensor-expressing cells (Epac1-camps YFP signal versus β 1 -AR sensor YFP signal, 440 ± 460 versus 2290 ± 320 AU; n = 6 and 7, respectively). Together, these data indicate that the β 1 -AR sensor is properly targeted to the cell surface and retains essential binding and signaling properties of the unlabeled receptor.
Dynamics of receptor conformational changes. Determination of FRET signals from single cells after agonist stimulation allowed the analysis of the activation kinetics of the β 1 -AR ( Figure 2 , D and E). Under all conditions, the decrease of the FRET ratio followed a monoexponential time course and was thus fitted to the equation f(t) = A(1 - e -t/τ ), (e is the number of Euler) where f(t) is function of time, A is the magnitude of the signal, and τ is the time constant. Consistent with the law of mass action, increasing concentrations of agonist resulted in shorter activation times (Figure 2E ). As shown in Figure 2E , under saturating conditions, the β 1 -AR is activated with a time constant of about 60 ms. To deter- mine whether the presence of YFP in the third intracellular loop of the receptor limits the speed of the conformational change, we generated a second β 1 -AR sensor (β 1 -AR-FlAsH) in which a short sequence of 6 amino acids (CCPGCC) was inserted into the third intracellular loop instead of YFP. This sequence specifically binds a small molecule (fluorescein arsenical hairpin binder, FlAsH) that becomes highly fluorescent after binding and allows the detection of FRET between Cer and FlAsH (36, 39) . The FlAsH-based β 1 -AR sensor also responded with a decrease of the FRET ratio and a similar time constant of receptor activation (57 ± 3 ms; n = 4) in response to agonist activation, suggesting sterically unhindered receptor activation kinetics of the β 1 -AR sensor (data not shown).
Receptor polymorphisms' impact on receptor conformational changes. To assess the potential role of the naturally occurring Arg389 variants of the β 1 -AR in receptor activation, we generated an Arg389-β 1 -AR sensor by point mutating position 389 of the β 1 -AR sensor from glycine to arginine (see Figure 1A ). Upon expression in HEK293 cells, both the Gly389-β 1 -AR sensor and the Arg389-β 1 -AR sensor showed equal expression levels as determined by radioligand binding (Gly389 versus Arg389, 2.1 ± 0.3 versus 2.2 ± 0.2 pmol/mg membrane protein; n = 4) as well as equal YFP intensity (Gly389 versus Arg389, 2292 ± 316 versus 2052 ± 183 AU; n = 7 and 9, respectively). The Arg389 variant displayed a slightly increased sensitivity to NE (EC 50 Figure 1C) for the 2 receptor variants. This was not due to saturation of the Epac1 sensor, as adenylyl cyclase activation and phosphodiesterase inhibition significantly enhanced cAMP levels even after stimulation of the β 1 -AR with a high concentration of Iso (100 nM) (Supplemental Figure 2A) . In addition, we studied coupling of the β 1 -AR to Gs. Again, we used a FRET-based approach based on a YFP-labeled G protein αs subunit, a cyan fluorescent protein (CFP)-labeled γ 2 subunit, and a nonlabeled β 1 subunit (30, 40) (Supplemental Figure 1D ). HEK293 cells transfected with the unlabeled Gly389-β 1 -AR or Arg389-β 1 -AR and with Gαs-YFP, Gβ, and Gγ-CFP, respectively, were simultaneously stimulated with NE (100 μM) plus ICI 118551 (200 nM) to block β 2 -ARs. No difference in β 1 -AR-mediated Gs activation was observed between the 2 receptor variants (Supplemental Figure  1D ). In addition, we determined the basal (i.e., in the absence of agonist) cAMP levels that the 2 receptor variants generated. Both variants exhibited the same basal Epac1-FRET signal calculated from cells expressing the Epac1-camps and the unlabeled β-AR receptor variants (Supplemental Figure 2B) . Moreover, we assessed the maximal cAMP-generating capacity of the 2 receptor variants. To this end, we treated Gly389-β 1 -AR transfected cells and Arg389-β 1 -AR transfected cells with forskolin and the phosphodiesterase inhibitor IBMX (100 μM) (Supplemental Figure  2C ). Both cell lines exhibited very similar maximal cAMP levels, confirming our previous notion (the validity of cAMP determination; see Supplemental Figure 2B ) that the 2 receptor variants do not differ significantly with respect to their basal constitutive activity in terms of whole cell cAMP generation. We then compared the FRET signals of the 2 variants due to several antagonists currently in clinical use (Figure 3 ). In contrast with the agonist, which induced a decrease in the FRET ratio, bisoprolol, metoprolol, and carvedilol led to an increase in the FRET ratio, i.e., an active change of the receptor conformation, suggesting inverse agonist behavior (37) . Upon washout, the signals induced by these compounds were slowly reversed, which was compatible with their high affinity to the receptor and, consequently, slow dissociation. As equilibrium conditions regarding ligand receptor interactions cannot be reached within a feasible time frame for low ligand concentrations ( Figure 2D ), high concentrations of β-AR antagonists were studied. Compared with the modest increases of the β 1 -AR-FRET signal induced by bisoprolol and metoprolol, carvedilol induced a more than 2-fold greater increase of the FRET signal of the Gly389-β 1 -AR ( Figure 3A) . The 389-receptor polymorphism did not affect the response to metoprolol and bisoprolol, whereas Arg389-receptors responded more than 2-folds stronger to carvedilol than they did to metoprolol and bisoprolol.
The differences observed at the receptor level became even more pronounced at the level of the second messenger cAMP, as measured with the cAMP sensor. Whereas bisoprolol and metoprolol induced no decreases of cAMP, carvedilol led to a marked reduction of basal cAMP ( Figure 3B ), and again, the Arg389 variant of the β 1 -AR led to a much stronger basal cAMP reduction.
Studies in primary cardiomyocytes. We next studied the impact of the 389 polymorphism on cardiac rate control in primary cardiac myocytes (Figure 4) . We employed adenoviral gene transfer to express equal levels of the 2 variants of the β 1 -AR in primary rat cardiac myocytes (2.7 ± 0.2 pmol/mg for the Gly389 variant and 2.8 ± 0.4 pmol/mg for the Arg389 variant; n = 4 per group). Expression of the Arg389 variant led to a higher beating frequency compared with the Gly389 variant already under basal conditions. Cardiac myocytes carrying the Arg389 variant, but not those carrying the Gly389 variant of the β 1 -AR, responded to the treatment with carvedilol (1 μM) with a significant reduction (25%) of the beating frequency. The absence of an effect of carvedilol on Gly389-transfected cardiomyocytes is in line with data examining cAMP formation after lower concentrations of carvedilol (data not shown). Under these conditions, only the Arg389, and not Gly389, of the β 1 -AR, responded with a decrease of cAMP.
Discussion
The β-AR has served as a prototypical receptor in the study of cellular signaling mediated by G protein-coupled receptors (41) . Despite this receptor being among the most intensely studied G protein-coupled receptors, it has not been possible to assess the activation of the β 1 -AR in a direct manner. Recently, the use of GFP-based FRET has allowed the direct optical recording of G protein-coupled receptor activation (33) . Here, we have applied this technology to the human β 1 -AR.
This first direct determination of conformational changes of the β 1 -AR in living cells revealed several critical characteristics of this GPCR. The β 1 -AR is activated at a high speed of approximately 60 ms, thereby resembling several neurotransmitter receptors (33, 36) . We provide direct evidence that some beta blockers can induce a very distinct receptor conformation compared to that induced by agonists, which is compatible with inverse agonism at the β 1 -AR. Of clinical relevance, the 2 most frequent variants of the β 1 -AR (Gly389, 26% allele frequency, and Arg389, 74% allele frequency; ref. 10) differ dramatically in their response to beta blocker treatment, with the Arg389 variant being exquisitely sensitive to carvedilol.
We have investigated whether our β 1 -AR-FRET sensor truly retained the behavior of the native receptor. Multiple lines of evidence indicate that this is the case. The β 1 -AR sensor was properly targeted to the cell membrane; the vast majority of the FRET signal recorded thus derives from receptors in their native environment. The modified receptors displayed ligand binding affinities similar to those of the unlabeled receptor (38) , and their signaling Impact of receptor polymorphisms. (A) Receptor activation in cells expressing the Gly389-β1-AR sensor (white bars) or the Arg389-β1-AR sensor (red bars) after beta blocker application (100 μM metoprolol, bisoprolol, or carvedilol) (n = 5-13 per group). (B) Effects of beta blockers (100 μM) on cAMP levels in cells expressing the unlabeled Gly389-β1-AR (white bars) or the Arg389-β1-AR (red bars) (n = 8-12 per group). *P < 0.05, statistically significant differences. Biso, bisoprolol; meto, metoprolol; carv, carvedilol.
was entirely normal. As an additional control, to rule out the possibility that the activation kinetics of the receptor were not limited by the insertion of YFP into the third intracellular loop, we constructed a β 1 -AR sensor, where the YFP was replaced by a 6-amino acid sequence, which allows the binding of a small fluorescent dye (FlAsH). FRET-based analysis of the activation kinetics of this FlAsH receptor showed exactly the same characteristics as the original β 1 -AR sensor, effectively excluding a significant influence of the YFP located in the third intracellular loop. Taken together, our results demonstrate that our FRET sensors retain the essential properties of the parent β 1 -AR.
The ability to directly assess the activation of the human β 1 -AR was then employed to determine the effects of clinically used beta blockers on the receptor protein itself and on downstream signal transduction. Beta blockers are among the most effective therapeutic agents for the treatment of common cardiovascular disorders, such as hypertension, coronary artery disease, and heart failure (8) . Three different substances (bisoprolol, carvedilol, and metoprolol) are currently used for the treatment of heart failure, and there is an ongoing debate over whether these substances differ as to their effectiveness and, if so, what the molecular basis of such differences might be (8) . Based on second messenger data or complex parameters, such as force of contraction of isolated myocardial tissue, inverse agonist properties have been suggested by some and disputed by others (38, (42) (43) (44) . The β 1 -AR-FRET sensor allowed, for what we believe is the first time, the direct assessment of the effects of various β 1 -AR antagonists on receptor conformational changes. We observed that all antagonists studied induced conformational changes (increase of FRET signal) opposite to those of agonist effects, indicating that this differential movement of different receptor domains after ligand binding represents the molecular basis for agonism and inverse agonism at the β 1 -AR. Interestingly, the atypical beta blocker carvedilol was markedly more effective than metoprolol and bisoprolol both in inducing the inverse agonist conformation of the receptor protein and in decreasing basal cAMP levels.
These findings are in agreement with respect to the effect of carvedilol on heart rate control in Gly389-β 1 -AR-expressing mice (45) as well as cAMP-formation in Gly389-β 1 -AR-expressing cells (38) . Inverse agonistic properties have been described for metoprolol and bisoprolol, which we cannot confirm with the present study (42, 44) . Two recent studies assessed the impact of the 389 polymorphism on cardiac function in heart failure patients. While one study associated the Arg389 polymorphism with the beneficial effects of carvedilol (15), a second study found no significant association (46) .
However, these studies often investigated very complex systems, such as human tissue with highly variable catecholamine concentrations from heart failure patients, tissue from patients with unknown receptor polymorphism status, and cell lines or transgenic mice with long-term overexpression of the β-AR. In contrast, our current study is the first, to our knowledge, to directly assess the impact of various beta blockers on the conformational change of the β 1 -AR.
This study identified a unique property of carvedilol, which is likely to become clinically relevant. When we directly assessed how the most frequent receptor polymorphism influenced intrinsic properties of receptor activation, we found a dramatic hypersensitivity of the Arg389 variant to carvedilol. The Arg389 variant of the human β 1 -AR, which is present in the majority of individuals, displayed a 2-fold greater response to carvedilol than the so-called wild-type Gly389, which really is the second most frequent 389 variant. This pronounced change in receptor conformation transduced into downstream functional effects, as we found in experiments determining myocyte beating rate. In this physiologically relevant model, we also saw an enhanced beating frequency in cells expressing the Arg389 variant of the β 1 -AR under basal conditions, which is in line with a previous study (10) . Thus, while we did not find a significantly enhanced capacity of the Arg389-β 1 -AR variant to form cAMP under basal conditions in HEK cells (Supplemental Figure 2) , expression of the 2 receptor variants in primary rat cardiomyocytes revealed differences as to their chronotropic effect. This is most likely due to the cardiomyocyte environment, where localized submembrane cAMP has been shown to regulate channel activity (47, 48) , but cannot yet be resolved by Epac1-camps determination.
Both metoprolol and bisoprolol did not markedly affect cAMP of Arg389-β 1 -AR-expressing cells. Thus, carvedilol appears to be unique in its ability to suppress the chronically enhanced basal signaling of the Arg389 variant of the β 1 -AR. This finding is potentially of great clinical importance, as the presence of the Arg389 polymorphism has been suggested as determining a poor prognosis in heart failure patients.
The present data show, for what we believe is the first time, realtime measurements of β 1 -AR activation in living cells and provide
Figure 4
Supersensitivity of the Arg389-β1-AR polymorphism to carvedilol. (A) Representative tracings of the beating frequency of cardiomyocytes infected with the Gly389-β1-AR sensor or the Arg389-β1-AR sensor before and after stimulation with carvedilol (1 μM). The number of beats per minute was determined from the digitized video images by an observer who was blinded to the experimental protocol. (B) Effect of carvedilol (1 μM) on the beating frequency of cardiomyocytes infected with LacZ, the Gly389-β1-AR sensor, or the Arg389-β1-AR sensor (5 independent cardiomyocyte isolations each, including 5-10 measurements for each of the 6 groups). **P < 0.01 and ***P < 0.001, statistically significant differences. Ctrl, control.
evidence for supersensitivity of the frequent Arg389 variant of the β 1 -AR toward carvedilol. It will be interesting to investigate whether patients carrying the Arg389 polymorphism may benefit most from treatment with carvedilol as opposed to other beta blockers.
Methods
Molecular biology and cell culture. Constructions of recombinant β1-ARs (β1-AR sensor and β1-AR-FlAsH) were performed using Pfu DNA polymerase (Stratagene). Using a linker (GlyGlyGlyGlyGly), we fused the Cer variant of GFP (49) to the carboxy terminus of the β1-AR (AA 477). YFP (or the CCPGCC motif for FlAsH) was introduced into the third intracellular loop of the β1-AR at position 273. Site-directed mutagenesis at position 389 following a PCR strategy was carried out to generate the Arg389-β1-AR sensor construct (QuikChange II Site-Directed Mutagenesis kit; Stratagene). All constructs were verified by sequencing and subcloned into pTREXdest30 (Invitrogen) for eukaryotic expression. Unlabeled (Arg389-β1-AR and Gly389-β1-AR) and the sensor constructs of the β1-AR receptor, Epac1-camps (34), YFP-labeled G protein αs subunit (50) (kindly provided by C. Berlot, Weiss Center for Research, Geisinger Clinic, Danville, Pennsylvania, USA), CFP-labeled G protein γ2 subunit (51) , and G protein β1 subunit were expressed transiently by transfection using Effectene (QIAGEN) in HEK293 cells.
FRET measurements. Cells were split 24 hours after transfection and seeded on polylysine-coated coverslips. Cells were kept in culture for an additional 24 hours. For the FlAsH-β1-AR construct, FlAsH labeling was carried out on the day of the experiment as described (36) . Cells grown on coverslips were then maintained at room temperature in the FRET buffer (140 mM NaCl, 4.5 mM KCl, 10 mM Hepes, 2 mM CaCl2, 2 mM MgCl2, pH 7.4). FRET experiments were performed using a Zeiss-inverted microscope (Axiovert 200) equipped with an oil-immersion ×63 objective and a dual-emission photometric system (TIll Photonics) equipped with a polychrome IV light source (TIll Photonics). FRET was monitored as the emission ratio of YFP to Cer, F535/F480, where F535 and F480 are the emission intensities at 535 ± 15 nm and 480 ± 20 nm (505 nm DClP beam splitter) upon excitation at 436 ± 10 nm (beam splitter DClP 455 nm). The emission ratio was corrected by the respective spillover of Cer into the 535 nm channel and the direct excitation of YFP at 436 nm. To determine whether intermolecular FRET arising from varying expression levels of the FRET sensors employed would influence our results, we reanalyzed our data and calibrated them for the YFP signal recorded from each cell, thereby normalizing for receptor expression. Calibration for receptor expression did not alter the results as compared with the original data. To determine pharmacological stimulation-induced FRET changes, cells were continuously superfused with FRET buffer, and ligands were applied using the computer-assisted solenoid valve-controlled rapid superfusion device AlA-VM (AlA Scientific Instruments; solution exchange 5-10 ms). Signals detected by amplified photodiodes (TIll Photonics) were digitalized using an analog digitizer converter (Digidata 1322A; Axon Instruments) and stored on a personal computer using Clampex 9.0 software (Axon Instruments). Carvedilol was from SmithKline Beecham; NE, Iso, ICI 118551, propranolol, and metoprolol-tartrate were from Sigma-Aldrich; and bisoprolol fumarate was from Merck.
Confocal microscopy. Confocal microscopy was performed using a leica TCS SP2 system with an Attofluor holder (Invitrogen). YFP was excited with the 514-nm line of an argon laser, and images were taken with a ×63 objective using the factory settings for YFP fluorescence (530-600 nm).
Adenovirus generation. Recombinant adenoviral vectors were generated according to standard procedures. Gly389-β1-AR sensor and Arg389-β1-AR sensor were amplified by PCR and introduced into adenoviral vectors (pAD/CMV/V5-DEST; Invitrogen) by homologous recombination.
A corresponding lacZ-expressing adenoviral vector (pAd/CMV/lacZ) was used as control. Adenovirus titers were determined by plaque assays in HEK293 monolayer cultures embedded in agarose.
Cardiomyocyte isolation, adenoviral transfection, and contractile activity. Neonatal cardiomyocytes were isolated from hearts of 1- to 2-day-old Sprague Dawley rats by enzymatic digestion essentially as described previously (52) . Cardiomyocytes were plated on 96-well plates in medium containing 5% FCS. After 24 hours, medium was replaced by 1% FCS medium, and adenoviral transfection was performed at an MOI of 50. Contractile activity of cardiomyocytes was monitored 48 hours after infection. live cells were held thermostatically at 32°C and examined under a microscope with a ×63 oil-immersion objective; bright field images were recorded every 400 ms, and the number of beats per minute was determined from the digitized video images. Beating frequency was determined before and after pharmacological stimulation by an observer who was blinded to the experimental protocol. Cardiomyocyte contractility was measured using edge detection perpendicular to the outward cell edge using MetaMorph software (Visitron Systems). Contraction events were defined based on the inward movement (≥ 5 pixels, corresponding to 0.510 μM) of the cell edge toward the nucleus, resulting in a digital information of cell contractility.
Membrane preparation and radioligand-binding assays. Transfected HEK293 cells, infected cardiomyocytes, or native cells were washed with PBS, and membrane fractions were prepared as described (53) . The resulting membrane pellets were resuspended in 50 mM Tris buffer, pH 7.4. Protein concentrations were determined by the Bradford method using bovine serum albumin (Sigma-Aldrich) as standard. Radioligand-binding experiments were performed in 50 mM Tris-HCl, pH 7.4, in the presence of 100 μM GTP to ensure monophasic competition curves for agonists (38) . For competition binding experiments, we used 50 pM 125 I-CYP. Nonspecific binding was determined in the presence of 10 μM alprenolol.
Statistics. Average data are presented as mean ± SEM. Statistical analysis was carried out using the Prism software package (version 4.0; GraphPad Software). Statistical significance was evaluated by unpaired 2-tailed Student's t test. P < 0.05 was considered statistically significant.
